PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, making it one of the most valuable biotech companies in the country. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
PlasmaGen Biosciences is a leading player in the plasma fractionation industry, operating one of India’s five plasma fractionation facilities near Bengaluru. The company’s state-of-the-art facility is equipped to process large quantities of plasma, which is used to manufacture life-saving therapies for various diseases. PlasmaGen’s products are used to treat a range of conditions, including hemophilia, immunodeficiency disorders, and infectious diseases.
The funding round led by ViNS Bioproducts is a testament to the company’s growth potential and the increasing demand for plasma-based therapies in India and globally. The investment will be used to expand PlasmaGen’s manufacturing capacity, enhance its research and development capabilities, and strengthen its distribution network.
PlasmaGen’s journey began with a vision to provide access to affordable and high-quality plasma-based therapies to patients in India and other emerging markets. The company’s founders, a team of experienced biotechnology professionals, recognized the vast potential of the plasma fractionation industry and the need for a reliable and sustainable supply of plasma-based products.
Over the years, PlasmaGen has established itself as a trusted partner for hospitals, pharmaceutical companies, and research institutions, providing them with high-quality plasma and plasma-based products. The company’s commitment to quality, safety, and customer satisfaction has earned it a reputation as a leader in the industry.
The plasma fractionation industry is a complex and highly regulated sector, requiring significant investment in infrastructure, technology, and talent. PlasmaGen’s success is a reflection of its ability to navigate these challenges and build a world-class organization that meets the highest standards of quality and safety.
The funding round led by ViNS Bioproducts is also a validation of the Indian biotechnology sector’s growth potential. India has emerged as a hub for biotechnology innovation, with several companies making significant strides in areas such as vaccine development, gene therapy, and regenerative medicine.
The government’s initiatives to promote biotechnology innovation, such as the Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology (DBT), have created a favorable ecosystem for companies like PlasmaGen to thrive. The presence of prominent investors such as Eight Roads, FIL Capital, and F-Prime has also helped to attract talent and capital to the sector.
As PlasmaGen continues to grow and expand its operations, it is likely to play an increasingly important role in shaping the Indian biotechnology sector. The company’s commitment to innovation, quality, and customer satisfaction has earned it a reputation as a leader in the industry, and its success is likely to inspire other entrepreneurs and companies to pursue opportunities in the biotechnology sector.
In conclusion, PlasmaGen’s ₹150 crore funding round is a significant milestone for the company and the Indian biotechnology sector. With a valuation of over ₹1,500 crore, PlasmaGen is well-positioned to continue its growth trajectory and make a meaningful impact on the lives of patients in India and globally. As the company expands its operations and strengthens its capabilities, it is likely to remain a leader in the plasma fractionation industry and a symbol of Indian biotechnology innovation.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
